title: Risk of venous thromboembolism in patients with cancer: a systematic review and meta-analysis.
abstract: BACKGROUND
  People with cancer are known to be at increased risk of venous thromboembolism (VTE), and this risk is believed to vary according to cancer type, stage of disease, and treatment modality. Our purpose was to summarise the existing literature to determine precisely and accurately the absolute risk of VTE in cancer patients, stratified by malignancy site and background risk of VTE.
  
  
  RESULTS
  We searched the Medline and Embase databases from 1 January 1966 to 14 July 2011 to identify cohort studies comprising people diagnosed with one of eight specified cancer types or where participants were judged to be representative of all people with cancer. For each included study, the number of patients who developed clinically apparent VTE, and the total person-years of follow-up were extracted. Incidence rates of VTE were pooled across studies using the generic inverse variance method. In total, data from 38 individual studies were included. Among average-risk patients, the overall risk of VTE was estimated to be 13 per 1,000 person-years (95% CI, 7 to 23), with the highest risk among patients with cancers of the pancreas, brain, and lung. Among patients judged to be at high risk (due to metastatic disease or receipt of high-risk treatments), the risk of VTE was 68 per 1,000 person-years (95% CI, 48 to 96), with the highest risk among patients with brain cancer (200 per 1,000 person-years; 95% CI, 162 to 247). Our results need to be considered in light of high levels of heterogeneity, which exist due to differences in study population, outcome definition, and average duration of follow-up between studies.
  
  
  CONCLUSIONS
  VTE occurs in greater than 1% of cancer patients each year, but this varies widely by cancer type and time since diagnosis. The absolute VTE risks obtained from this review can aid in clinical decision-making about which people with cancer should receive anticoagulant prophylaxis and at what times.
authors.affiliation: Division of Epidemiology and Public Health, University of Nottingham, Nottingham, United Kingdom.
authors.forename: Freesia
authors.initials: F
authors.lastname: Horsted
authors.forename: Joe
authors.initials: J
authors.lastname: West
authors.forename: Matthew J
authors.initials: MJ
authors.lastname: Grainge
mesh_terms: D005500:Follow-Up Studies; D006801:Humans; D009369:Neoplasms / Q000145:classification / Q000150:complications* / Q000175:diagnosis / Q000628:therapy; D012307:Risk Factors; D054556:Venous Thromboembolism / Q000453:epidemiology* / Q000209:etiology*